| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
RAPID COMMUNICATION |
Division of Geriatric Medicine (A.J., N.S.F., M.A.A.), Department of Medicine, Johns Hopkins University, Baltimore, Maryland 21224; General Clinical Research Center (N.S.F., R.G., M.T.), Johns Hopkins Bayview Medical Center, Baltimore Maryland 21224; and Craniofacial and Skeletal Diseases Branch (M.T.C., L.W.F.), National Institute of Dental and Craniofacial Research, National Institutes of Health, DHHS, Bethesda, Maryland 20892
Address all correspondence and requests for reprints to: Neal S. Fedarko, Division of Geriatric Medicine, Johns Hopkins Bayview Medical Center, 5501 Hopkins Bayview Circle, Room 5B 79 JHAAC, Baltimore, Maryland 21224. E-mail: ndarko{at}welchlink.welch.jhu.edu
Abstract
Matrix extracellular phosphoglycoprotein (MEPE), a member of the Small Integrin Binding Ligand N-linked Glycoprotein (SIBLING) family, is primarily expressed in normal bone and has been proposed as a phosphaturic factor because of high expression and secretion in oncogenic hypophosphatemic osteomalacia tumors. In order to begin to address the role of MEPE in normal human physiology, we developed a competitive ELISA to measure serum levels of MEPE. The ELISA was used to characterize the distribution pattern in a population consisting of 114 normal adult subjects. The mean value of MEPE was 476 ± 247 ng/ml and levels decreased significantly with increasing age. MEPE levels were also significantly correlated with serum phosphorus and parathyroid hormone (PTH). In addition, MEPE levels correlated significantly with measures of bone mineral density in the femoral neck and total hip in a subset of 50 elderly subjects. The results are consistent with MEPE being involved in phosphate and bone metabolism in a normal population.
Received November 25, 2004.
Accepted March 22, 2004.
This article has been cited by other articles:
![]() |
A. Martin, V. David, J. S. Laurence, P. M. Schwarz, E. M. Lafer, A.-M. Hedge, and P. S. N. Rowe Degradation of MEPE, DMP1, and Release of SIBLING ASARM-Peptides (Minhibins): ASARM-Peptide(s) Are Directly Responsible for Defective Mineralization in HYP Endocrinology, April 1, 2008; 149(4): 1757 - 1772. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Dobbie, R. J. Unwin, N. J. R. Faria, and D. G. Shirley Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption Nephrol. Dial. Transplant., February 1, 2008; 23(2): 730 - 733. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Six, D. Septier, C. Chaussain-Miller, R. Blacher, P. DenBesten, and M. Goldberg Dentonin, a MEPE Fragment, Initiates Pulp-healing Response to Injury J. Dent. Res., August 1, 2007; 86(8): 780 - 785. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Liu, P. S N Rowe, L. Vierthaler, J. Zhou, and L D. Quarles Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity J. Endocrinol., January 1, 2007; 192(1): 261 - 267. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Garringer, C. Fisher, T. E. Larsson, S. I. Davis, D. L. Koller, M. J. Cullen, M. S. Draman, N. Conlon, A. Jain, N. S. Fedarko, et al. The Role of Mutant UDP-N-Acetyl-{alpha}-D-Galactosamine-Polypeptide N-Acetylgalactosaminyltransferase 3 in Regulating Serum Intact Fibroblast Growth Factor 23 and Matrix Extracellular Phosphoglycoprotein in Heritable Tumoral Calcinosis J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4037 - 4042. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. White, T. E. Larsson, and M. J. Econs The Roles of Specific Genes Implicated as Circulating Factors Involved in Normal and Disordered Phosphate Homeostasis: Frizzled Related Protein-4, Matrix Extracellular Phosphoglycoprotein, and Fibroblast Growth Factor 23 Endocr. Rev., May 1, 2006; 27(3): 221 - 241. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Berndt, S. Schiavi, and R. Kumar "Phosphatonins" and the regulation of phosphorus homeostasis Am J Physiol Renal Physiol, December 1, 2005; 289(6): F1170 - F1182. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Imel and M. J. Econs Fibroblast Growth Factor 23: Roles in Health and Disease J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2565 - 2575. [Full Text] [PDF] |
||||
![]() |
N. Matsumoto, O. D. Jo, R. N. J. Shih, E. J. Brochmann, S. S. Murray, V. Hong, J. Yanagawa, and N. Yanagawa Increased cathepsin D release by Hyp mouse osteoblast cells Am J Physiol Endocrinol Metab, July 1, 2005; 289(1): E123 - E132. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Bresler, J. Bruder, K. Mohnike, W. D Fraser, and P. S N Rowe Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets J. Endocrinol., December 1, 2004; 183(3): R1 - R9. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Strewler Phos, Phex and FGF: Mysteries of Phosphate Homeostasis Revealed - or Still Hidden IBMS BoneKEy, September 1, 2004; 1(9): 6 - 14. [Full Text] [PDF] |
||||
![]() |
P. S.N. Rowe THE WRICKKENED PATHWAYS OF FGF23, MEPE AND PHEX Crit. Rev. Oral. Biol. Med., September 1, 2004; 15(5): 264 - 281. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |